

Electroconvulsive Therapy: Solution or a Cause of Tardive Dyskinesia?

Varela Piñón María* and Inmaculada Octavio del Valle

Department of Psychiatry, Hospital Universitario de La Princesa, Madrid, Spain

Abstract

Tardive dyskinesia is a motor disorder characterized by the appearance of involuntary and irregular movements in different body regions. It is usually caused by prolonged use of dopamine receptor blocking agents, especially by taking antipsychotics. Currently, there is no curative treatment for this disorder, although there are pharmacological strategies that reduce its impact. Electroconvulsive therapy has been successfully applied in several cases of tardive dyskinesia and has been proposed as a therapeutic alternative, although the available evidence is still insufficient. In the present article, we present a case of tardive dyskinesia which emerged following the application of electroconvulsive therapy. It is considered if there could be a relation between the application of this technique and the appearance of the motor disorder in specially predisposed individuals.

Keywords: Electroconvulsive therapy; Tardive dyskinesia; Major depression

Introduction

Tardive dyskinesia (TD) is a motor disorder resulting in involuntary, repetitive movements in areas such as mouth, tongue, face, trunk or limbs [1]. It is usually caused by prolonged use of dopamine receptor blocking agents, such as some antidepressants, antiepileptics or antiemetics, and is especially common due to the prolonged taking of antipsychotics [1-3]. Currently, there is no treatment that eliminates them, although there are diverse pharmacological strategies that reduce their impact, such as tetrabenazine or some antioxidant agents [2]. Electroconvulsive therapy (ECT) has been used several times to reduce TD with favourable results [1], although the level of evidence is still insufficient to propose it as a curative treatment [2]. Further on, we present a case of TD, which emerged after the application of ECT, and we propose whether there may be a relation between the appearance of the motor disorder and the application of this therapy. A comprehensive research has been conducted through evidence-based clinical resource such as Up-to-date, BMJ Clinical Evidence, Clinical Key, Medline and PubMed.

Case Report

An 85-year-old man, who had no relevant medical-surgical history, with a major depression refractory to various pharmacological treatments was admitted to the hospital. Since the onset of depression, the patient had received treatment with different groups of antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs), Selective Dopamine Reuptake Inhibitors and Norepinephrine (IRDN), Mono-Amino Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants and Tetracyclic Antidepressants. In addition, he had been on treatment with mood stabilizers and with 2.5 mg of olanzapine during 1 month, without ever achieving a remission of the depressive symptomatology. The first time he came to our clinic, about 2 years ago, he was being treated with desvenlafaxine at a dose of 100 mg per day. Due to the lack of improvement of the depressive clinic and to the appearance of delusional symptoms, he was treated with 9 sessions of ECT. Besides, the antidepressant was replaced by bupropion at doses of 150 mg daily and neuroleptic medication was introduced (risperidone at doses of 2 mg/day), achieving a partial remission of the symptomatology. In the next months, the depressive episode got worse, appearing autolytic ideation, so the bupropion dose was increased to 300 mg daily, with

the neuroleptic treatment being maintained at the previous doses. In addition, he received supportive therapy with cognitive-behavioural intervention with cognitive restructuring, coping strategies and stress reduction, but it was unsuccessful. A few weeks later it was decided to maximize the antidepressant regime and add mirtazapine 15 mg/day. Parkinsonism symptoms (bradykinesia and rigidity) were observed 3 months later, which was assessed by Neurology. A pharmacological origin of the motor disorder was suspected, so it was decided to suspend the treatment with 2 mg of risperidone, which the patient had taken for a year and a half. A partial improvement of the motor clinic was observed. The following weeks the affective symptomatology worsened. Further pharmacological readjustments (replacement of bupropion by desvenlafaxine 100 mg/day and subsequent dose increase to 150 mg daily, keeping mirtazapine at the previous doses) were equally ineffective. In the absence of positive results, it was decided to process another in-patient admission to reapply ECT. Seven sessions were administered, without observing a clear remission of the affective disorder. He also received supportive therapy with cognitive-behavioural intervention, without satisfactory results.

One week after the end of the ECT, involuntary movements at the or mandibular level, increasingly marked, were observed. These movements caused several mouth injuries from bites, pain and difficult food intake, and improved at night coinciding with sleep. The case was again evaluated by Neurology, which ruled out a parkinsonian disorder of neurological etiology and diagnosed tardive dyskinesia with a probable pharmacological cause. Benzodiazepine treatment was introduced in ascending pattern, with no response. Currently, the patient is being treated with 75 mg desvenlafaxine and 15 mg mirtazapine daily. An attempt was made to reduce the dose of desvenlafaxine in case it could be favouring the maintenance of the movements, but a clear deterioration of the depressive symptomatology was observed, with the appearance of irritability and decreased mood, so it was decided

*Corresponding author: María Varela Piñón, Department of Psychiatry, Hospital University of La Princesa, Madrid, Spain, Tel: +679861506; E-mail: maria.varela.pinon@gmail.com

Received April 12, 2017; Accepted April 19, 2017; Published April 21, 2017

Citation: Varela Piñón M, Del Valle IO (2017) Electroconvulsive Therapy: Solution or a Cause of Tardive Dyskinesia? J Depress Anxiety S11:003. doi:10.4172/2167-1044.S11-003

Copyright: © 2017 Varela Piñón M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

to maintain the dose at 75 mg/day. The dyskinesic movements are still present currently, they have increased their intensity and have spread to the trunk. They are becoming more and more disabling as they have caused a progressive loss of weight and, in addition, a frank emotional deterioration (pessimism, death thoughts) due to the limitations that they cause to him.

Discussion

The ECT uses a small electric current to produce a generalized cerebral seizure under general anesthesia [4]. It is mainly used in severe depression [5-8], although its use is also indicated in some cases of bipolar affective disorder, schizophrenia, schizoaffective disorder, catatonia, neuroleptic malignant syndrome or tardive dyskinesia [9,10].

Before starting ECT, it is recommendable to perform a complete medical evaluation and to explore possible antecedents that may contraindicate this therapy, such as cardiopulmonary diseases, central nervous system or major surgical interventions [11-14]. In our case, the patient had no relevant medical or surgical history that contraindicated its application, so the procedure was carried out in the usual way.

This technique may cause side effects of different severity [15]. Among the most common, and the mildest side effects, are headache [16-18], nausea or myalgias [19], as well as effects at a cognitive level that are often self-limited and require symptomatic management [20-22]. Other more severe but uncommon side effects include cardiac, pulmonary and cerebrovascular disorders. TD is not described as a possible direct side effect of the ECT application.

Many psychotropic medications, such as antidepressants [23], antipsychotics [24,25] or lithium [26], may be maintained during the course of ECT because of their synergistic effect, without compromising the safety or efficacy of the process [27,28]. Anticonvulsants [29] and benzodiazepines [30] interfere with ECT and it is recommended to be discontinued. In this case, antidepressant therapy was maintained during therapy (desvenlafaxine and mirtazapine, at a dose of 150 mg and 15 mg daily, respectively).

The ECT usually lasts from 6 to 12 sessions, and it's applied with a frequency of 2 or 3 times weekly to alternate days [31]. Our patient received 7 sessions, on a biweekly basis, without observing any significant change. Four days after the last session began to present dyskinesic movements at oromandibular level.

TD tends to appear in prolonged treatments with dopaminergic receptor blocking agents, being common due to the sustained intake of antipsychotics [32]. After withdrawal of neuroleptics, they usually remit in the course of months or years, although they sometimes persist in a chronic form [32]. However, it is important to note that not all patients receiving antipsychotics will develop TD. The reasons why only some of them present TD are still unknown. A number of factors have been proposed that could favour its emergence. Age is the risk factor that is most strongly associated with TD. It is suspected that at an older age there is an increased risk of developing this disorder and with a greater severity [33-35]. The existence of affective disorders, especially a major depressive disorder, neurological disease, or serious alcohol dependence, could be other factors predisposing to its development [36]. Cerebral structural abnormalities, cognitive deterioration, smoking or diabetes have been studied as possible factors favouring TD, without being able to be confirmed [37].

Neither there is a clear predisposition based on sex [38,39] although it could be somewhat higher in postmenopausal women [39].

Our patient was elderly, had major depressive disorder and prolonged exposure to antipsychotics (treatment with risperidone at a dose of 2 mg daily for approximately a year and a half) as significant risk factors, although neuroleptic medication had been withdrawn 6 months earlier of the appearance of TD. The possible role of desvenlafaxine in the maintenance or worsening of movements was studied, although TD was not described as a possible side effect of the use of this antidepressant.

For all of the above, we raised the possibility that the TD was triggered by the application of ECT, or alternatively, that it was a consequence of the neuroleptic treatment maintained where the ECT acted as a precipitant of the motor disorder, although the patient had already been without antipsychotics for 6 months and, until the application of ECT, did not present dyskinesic movements. Another hypothesis could be that ECT may have been a trigger precipitant of the symptomatology of an underlying primary disorder.

The current literature on the relationship between ECT and TD are scarce [1,40,41], which prevents us from knowing the actual influence of ECT on the appearance of these dysfunctional movements. Further knowledge about the mechanism of action of ECT is needed to ascertain its possible influence on the development of this neurological disorder.

After an exhaustive literature review, we have not found any other case that describes a possible relationship between the application of ECT and the occurrence of TD, although in the case discussed above it seems that this technique may have influenced somehow the development of the motor disorder.

Conclusion

Although ECT has been successfully employed in the management of TD, the case studied suggests that the application of this technique, in specially predisposed individuals, could influence somehow the appearance of dyskinesic disorders. Further studies are needed to help us understand the actual role of ECT in the development of TD and the mechanism by which this therapy could trigger its onset.

Conflicts of Interest and Source of Funding

The authors report no financial or ethical conflicts of interest regarding the content of the manuscript.

References

1. Peng LY, Lee Y, Lin PY (2013) Electroconvulsive therapy for a patient with persistent tardive dyskinesia: A case report and literature review. *J ECT* 29(3): e52-54.
2. Seigneurie AS, Sauvanaud F, Limosin F (2016) Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs. *Encephale* 42(3): 248-254.
3. Barberán M (2014) A clinical and therapeutic review. *Psiquiatr Biol* 21: 9-13.
4. Kellner C (2011) Technique for performing electroconvulsive therapy (ECT) in adults.
5. American Psychiatric Association (2010) Practice guideline for the treatment of patients with major depressive disorder. *Am J Psychiatry* 167.
6. Lisanby SH (2007) Electroconvulsive therapy for depression. *N Engl J Med* 357: 1939.
7. Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, et al. (2012) ECT in treatment-resistant depression. *Am J Psychiatry* 169: 1238-1244.
8. Ota M, Noda T, Sato N, Okazaki M, Ishikawa M, et al. (2015) Effect of electroconvulsive therapy on gray matter volume in major depressive disorder. *J Affect Disord* 186: 186-191.
9. Shorter E, Healy D (2007) *Shock therapy: A history of electroconvulsive treatment in mental illness*. Rutgers University Press, New Brunswick 2007.

10. Rasmussen KG, Rummans TA, Richardson JW (2002) Electroconvulsive therapy in the medically ill. *Psychiatr Clin North Am* 25: 177-193.
11. Kramer BA (1999) Use of ECT in California. Revisited: 1984-1994. *JECT* 15: 245.
12. Abrams R (1997) The mortality rate with ECT. *Convuls Ther* 13: 125.
13. Shiwach RS, Reid WH, Carmody TJ (2001) An analysis of reported deaths following electroconvulsive therapy in Texas, 1993-1998. *Psychiatr Serv* 52: 1095-1097.
14. Watts BV, Groft A, Bagian JP, Mills PD (2011) An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. *JECT* 27: 105-108.
15. Andrade C, Arumugham SS, Thirthalli J (2016) Adverse effects of electroconvulsive therapy. *Psychiatr Clin North Am* 39(3): 513-530.
16. Datto CJ (2000) Side effects of electroconvulsive therapy. *Depress Anxiety* 12: 130-134.
17. Devanand DP, Polanco P, Cruz R, Shah S, Paykina N, et al. (2000) The efficacy of ECT in mixed affective states. *JECT* 16: 32-37.
18. Weiner SJ, Ward TN, Ravaris C (1994) Headache and electroconvulsive therapy. *Headache* 34: 155-159.
19. Rasmussen KG, Petersen KN, Sticka JL, Wieme LJ, Zosel JH, et al. (2008) Correlates of myalgia in electroconvulsive therapy. *JECT* 24: 84-87.
20. Semkovska M, McLoughlin DM (2010) Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. *Biol Psychiatry* 68: 568-577.
21. Fernie G, Bennett DM, Currie J, Perrin JS, Reid IC (2014) Detecting objective and subjective cognitive effects of electroconvulsive therapy: Intensity, duration and test utility in a large clinical sample. *Psychol Med* 44: 2985-2994.
22. Porter R, Heenan H, Reeves J (2008) Early effects of electroconvulsive therapy on cognitive function. *JECT* 24: 35-39.
23. Baghai TC, Marcuse A, Brosch M, Schüle C, Eser D, et al. (2006) The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. *World J Biol Psychiatry* 7: 82-90.
24. Klapheke MM (1993) Combining ECT and antipsychotic agents: Benefits and risks. *Convuls Ther* 9: 241-255.
25. Nothdurfter C, Eser D, Schüle C, Zwanzger P, Marcuse A, et al. (2006) The influence of con-comitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. *World J Biol Psychiatry* 7: 162-170.
26. Dolenc TJ, Rasmussen KG (2005) The safety of electroconvulsive therapy and lithium in combination: A case series and review of the literature. *JECT* 21: 165-170.
27. American Psychiatric Association (2001) Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: Recommendations for treatment, training, and privileging. American Psychiatric Association, Washington.
28. Sackeim HA, Dillingham EM, Prudic J (2009) Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. *Arch Gen Psychiatry* 66: 729.
29. Sienaert P, Peuskens J (2007) Anticonvulsants during electroconvulsive therapy: Review and recommendations. *JECT* 23: 120-123.
30. Greenberg RM, Pettinati HM (1993) Benzodiazepines and electroconvulsive therapy. *Convuls Ther* 9: 262-273.
31. Charlson F, Siskind D, Doi SA (2012) ECT efficacy and treatment course: A systematic review and meta-analysis of twice vs thrice weekly schedules. *J Affect Disord* 138: 1-8.
32. Mattay VS, Casey DE (1993) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. *Schizophrenia* 16: 552-572.
33. Chouinard G, Annable L, Roos-Chouinard A, Mercier P (1988) A five year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. *J Clin Psychopharmacol* 8: 21-26.
34. Yassa R, Nastase C, Dupont D, Thineau M (1992) Tardive dyskinesia in elderly psychiatric patients: A five year study. *Am J Psychiatry* 149: 1206-1211.
35. Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak RE, McEachran A (1995) Duration of neuroleptic treatment and prevalence of Tardive dyskinesia in late life. *Arch Gen Psychiatry* 52: 478-486.
36. Kane JM, Woerner M, Lieberman J (1985) Tardive dyskinesia: Prevalence, incidence and risk factors. *J Clin Psychopharmacol* 8: 52-56.
37. Davis K, Berger P, Hollister L (1976) Tardive dyskinesia and depressive illness. *Psychopharmacol Commun* 2: 125-130.
38. Morgenstern H, Glazer WM (1993) Results of the Yale Tardive Dyskinesia Study. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. *Arch Gen Psychiatry* 50: 723-733.
39. Smith JM, Oswald WT, Kucharski LT, Waterman LJ (1978) Tardive dyskinesia: Age and sex differences in hospitalized schizophrenics. *Psychopharmacology* 58: 207-211.
40. Yasui-Furukori N, Kikuchi A, Katagai H, Kaneko S (2014) The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: A retrospective study. *Neuropsychiatr Dis Treat* 10: 1209-1212.
41. Sunwoo JS, Jung DC, Choi JY, Kang UG, Lee ST, et al. (2016) Successful treatment of refractory dyskinesia secondary to Anti-N-Methyl-D-Aspartate receptor encephalitis with electroconvulsive therapy. *JECT* 32(3): e13-e14.

This article was originally published in a special issue, **Depression in Cancer Patients** handled by Editor(s). Dr. Domenico Chirchiglia, Chair of Neurosurgery, University of Catanzaro, Italy